The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The U.S. Food and Drug Administration (FDA) has approved a new pain pill called Journavx, designed to mitigate the risks of addiction and overdose associated with opioid medications like Vicodin and ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The FDA has approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid ...